Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When would you use ofatumumab for anti-NMDAR autoimmune encephalitis?
In light of publication from Guo et al in Ann Neurol 2025 Jul
https://doi.org/10.1002/ana.27218
Related Questions
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
What are red flags in an evaluation for possible multiple sclerosis that should prompt workup for genetic/inherited conditions?
What are your vaccine recommendations while patients are on biologics?
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
How do you decide on long term immunosuppression therapy for Susac Syndrome?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
How do you handle medication management for patients on immunosuppressive therapy who are lost to follow-up?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
When do you switch to a different DMT in multiple sclerosis patients planning for pregnancy?